On August 7, 10x Genomics, Inc. rose 5.26% in regular trading, trading at 48.12 USD/share, with turnover of $58.40 million.

On the news front, the company reported Q2 results with a per-share loss of $0.14, significantly better than the analyst consensus estimate of a $0.24 loss, representing a 41.67% beat. Revenue of $151.0 million also exceeded the expected $146.7 million. Additionally, the company raised its full-year revenue guidance to $610 million-$630 million, up from prior guidance of $600 million-$625 million and above the analyst estimate of $613.7 million.

While Q2 revenue declined 12.7% year-over-year from $172.9 million and the company swung to a loss from EPS of $0.28 a year earlier, the substantial earnings beat combined with the upward guidance revision signaled improving fundamentals. After initially declining approximately 5% in after-hours and pre-market sessions following the report, the stock reversed sharply during regular trading as investors digested the positive guidance revision and better-than-expected profitability trajectory.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)